Online inquiry

IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6495MR)

This product GTTS-WQ6495MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6495MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1933MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGS15C
GTTS-WQ7662MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GEN-1029
GTTS-WQ5007MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA c4G7-N
GTTS-WQ8867MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ3179MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ14238MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RG-6107
GTTS-WQ8741MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ7864MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK-2398852
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW